• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫相关肿瘤反应标准和接受依匹单抗治疗患者免疫相关不良事件模式的放射学特征。

Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.

机构信息

Department of Radiology, Dana-Farber Cancer Institute and Melanoma Disease Center, Dana-Farber/Brigham and Women's Cancer Center, 44 Binney St, Boston, MA 02115, USA.

出版信息

AJR Am J Roentgenol. 2011 Aug;197(2):W241-6. doi: 10.2214/AJR.10.6032.

DOI:10.2214/AJR.10.6032
PMID:21785048
Abstract

OBJECTIVE

The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab.

CONCLUSION

Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.

摘要

目的

本文旨在举例说明接受免疫治疗药物伊匹单抗治疗的晚期黑色素瘤患者的影像学免疫相关反应标准和毒性。

结论

对于接受伊匹单抗治疗的晚期黑色素瘤患者，应采用新型免疫相关肿瘤反应标准。伊匹单抗还会产生一系列可在影像学上识别的免疫相关不良反应。

相似文献

1
Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.免疫相关肿瘤反应标准和接受依匹单抗治疗患者免疫相关不良事件模式的放射学特征。
AJR Am J Roentgenol. 2011 Aug;197(2):W241-6. doi: 10.2214/AJR.10.6032.
2
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.依匹木单抗的研发：为癌症免疫治疗开创新模式。
Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015.
3
Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.接受抗 CTLA-4 抗体治疗的转移性黑色素瘤患者免疫相关不良事件的放射学表现。
AJR Am J Roentgenol. 2011 Dec;197(6):W992-W1000. doi: 10.2214/AJR.10.6198.
4
Ipilimumab in advanced melanoma: reports of long-lasting responses.依匹单抗治疗晚期黑色素瘤：持久缓解反应的报告。
Melanoma Res. 2012 Jun;22(3):263-70. doi: 10.1097/CMR.0b013e328353e65c.
5
Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.使用氟代脱氧葡萄糖正电子发射断层扫描-计算机断层扫描（FDG PET-CT）进行伊匹单抗免疫治疗黑色素瘤时的免疫介导疾病
Acad Radiol. 2017 Jan;24(1):111-115. doi: 10.1016/j.acra.2016.08.005. Epub 2016 Nov 4.
6
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.接受过伊匹单抗的晚期黑色素瘤患者在先前II期研究中的生存随访及伊匹单抗再治疗情况。
Ann Oncol. 2014 Nov;25(11):2277-2284. doi: 10.1093/annonc/mdu441. Epub 2014 Sep 10.
7
Ipilimumab-Associated Retinopathy.伊匹单抗相关性视网膜病变
Ophthalmic Surg Lasers Imaging Retina. 2015 Jun;46(6):658-60. doi: 10.3928/23258160-20150610-10.
8
Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.免疫检查点抑制剂治疗晚期黑色素瘤患者的免疫相关不良事件的影像学特征
Cancer Immunol Res. 2015 Oct;3(10):1185-92. doi: 10.1158/2326-6066.CIR-15-0102. Epub 2015 Jun 22.
9
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.易普利姆玛：通过 CTLA-4 阻断释放免疫系统的力量。
Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004.
10
Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.黑色素瘤序贯免疫治疗导致的非典型严重免疫相关不良反应。
Melanoma Res. 2015 Apr;25(2):178-9. doi: 10.1097/CMR.0000000000000132.

引用本文的文献

1
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.癌症免疫治疗中的肝毒性：诊断、管理及未来展望。
Cancers (Basel). 2024 Dec 29;17(1):76. doi: 10.3390/cancers17010076.
2
Treatment-induced sarcoidosis in a patient with metastatic clear cell ovarian cancer.转移性透明细胞卵巢癌患者的治疗相关性肉瘤病。
BMJ Case Rep. 2021 Dec 7;14(12):e247278. doi: 10.1136/bcr-2021-247278.
3
Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.一线帕博利珠单抗治疗晚期非小细胞肺癌患者的肿瘤反应动力学。
JCO Precis Oncol. 2021 Mar 19;5. doi: 10.1200/PO.20.00478. eCollection 2021.
4
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.癌症免疫疗法毒性综述：免疫检查点抑制剂。
J Med Toxicol. 2021 Oct;17(4):411-424. doi: 10.1007/s13181-021-00833-8. Epub 2021 Apr 7.
5
Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.免疫检查点抑制剂治疗的癌症患者中的类肉瘤样反应：一家西班牙医院的经验。
Clin Transl Oncol. 2021 Jul;23(7):1474-1480. doi: 10.1007/s12094-020-02546-w. Epub 2021 Jan 12.
6
Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.免疫治疗不良反应的腹部 CT 表现：放射科医师入门。
Abdom Radiol (NY). 2020 Sep;45(9):2624-2636. doi: 10.1007/s00261-020-02531-5.
7
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.抗 PD-1 抗体治疗后超出 RECIST 进展的黑色素瘤患者：美国食品和药物管理局的汇总分析。
Lancet Oncol. 2018 Feb;19(2):229-239. doi: 10.1016/S1470-2045(17)30846-X. Epub 2018 Jan 18.
8
Immune-related tumour response assessment criteria: a comprehensive review.免疫相关肿瘤反应评估标准：全面综述。
Br J Radiol. 2018 Apr;91(1084):20170457. doi: 10.1259/bjr.20170457. Epub 2018 Feb 14.
9
Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.癌症治疗中免疫检查点抑制剂所致毒性的影像学特征
Curr Radiol Rep. 2016;5(11):59. doi: 10.1007/s40134-017-0256-2. Epub 2017 Sep 11.
10
Olmesartan-associated enteropathy.奥美沙坦相关小肠病
Proc (Bayl Univ Med Cent). 2017 Jul;30(3):348-350. doi: 10.1080/08998280.2017.11929644.